Cornea and external disease

FDA approves Verkazia for treatment of vernal keratoconjunctivitis

The U.S. Food and Drug Administration has approved Verkazia (cyclosporine ophthalmic emulsion; Santen Inc) 0.1% eye drops for the treatment of vernal keratoconjunctivitis (VKC) in children and adults, according to a press release.

“This is an important milestone in Santen’s aim to bring innovative solutions that protect vision for those affected by rare ophthalmic conditions, and is the first prescription product approval for Santen in the U.S. market,” said Tatsuya…

Read More


featured stories

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.

Conference Roundup

  1. Apr 13, 2021

Investigational therapy improves overall survival in metastatic uveal melanoma

Tebentafusp (IMCgp100; Immunocore) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-line treatment in patients with metastatic uveal melanoma, according to Phase 3 clinical trial results presented at the American Association for…

View All

Journal Scan

  1. Jun 15, 2021

Adjuvant cross-linking doesn’t appear beneficial for bacterial keratitis

Adjuvant cross-linking (CXL) did not appear beneficial in the primary treatment of moderate bacterial keratitis, according to clinical trial results published in Cornea. However, the researchers noted that CXL may reduce culture positivity and complication rates.…

View All

Trending Topics

  1. Jun 24, 2021

FDA approves Verkazia for treatment of vernal keratoconjunctivitis

The U.S. Food and Drug Administration has approved Verkazia (cyclosporine ophthalmic emulsion; Santen Inc) 0.1% eye drops for the treatment of vernal keratoconjunctivitis (VKC) in children and adults, according to a press release.…

View All

Resources